Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas

DMM Disease Models and Mechanisms

Volumn 9, Issue 4, 2016, Pages 441-449

  Morales, Maria Gabriela ^a,b   Abrigo, Johanna ^a,b   Acuna, Maria Jose ^c   Santos, Robson A ^d   Bader, Michael ^e,f   Brandan, Enrique ^c   Simon, Felipe ^a,b   Olguin, Hugo ^c   Cabrera, Daniel ^g,h   Cabello Verrugio, Claudio ^a,b  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b Pontificia Universidad Católica de Chile   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f National Institute of Science and Technology in Nanobiopharmaceutics   (Brazil)

^g UNIVERSIDAD BERNARDO O'HIGGINS   (Chile)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Angiotensin (1 7); Atrophy; Disuse; Mas receptor; Skeletal muscle

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; ATROGIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAS RECEPTOR; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); FBXO32 PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; MUSCLE PROTEIN; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; TRIM63 PROTEIN, MOUSE; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GASTROCNEMIUS MUSCLE; HINDLIMB; HINDLIMB MUSCLE; IMMOBILIZATION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE DISUSE ATROPHY; TIBIALIS ANTERIOR MUSCLE; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; MUSCLE ISOMETRIC CONTRACTION; MUSCULAR ATROPHY; MUSCULAR DISORDERS, ATROPHIC; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE CELL;

ANGIOTENSIN I; ANIMALS; INSULIN-LIKE GROWTH FACTOR I; ISOMETRIC CONTRACTION; MALE; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCULAR ATROPHY; MUSCULAR DISORDERS, ATROPHIC; MYOSIN HEAVY CHAINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; TRIPARTITE MOTIF PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84963700094     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.023390     Document Type: Article

References (42)

1. Acuna, M. J., Pessina, P., Olguin, H., Cabrera, D., and Vio, C. P., Bader, M., Munoz-Canoves, P., Santos, R. A., Cabello-Verrugio, C. and Brandan, E. (2014). Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling. Hum. Mol. Genet. 23, 1237-1249.
2. Bertagnolli, M., and Casali, K. R., De Sousa, F. B., Rigatto, K., Becker, L., Santos, S. H. S., Dias, L. D., Pinto, G., Dartora, D. R., Schaan, B. D. et al. (2014). An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats. Peptides 51, 65-73.
3. Bodine, S. C. (2013). Disuse-induced muscle wasting. Int. J. Biochem. Cell Biol. 45, 2200-2208.
4. Brooks, N. E. and Myburgh, K. H. (2014). Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways. Front. Physiol. 5, 99.
5. Burks, T. N., Andres-Mateos, E., Marx, R., Mejias, R., Van Erp, C., Simmers, J. L., and Walston, J. D., Ward, C. W. and Cohn, R. D. (2011). Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med. 3, 82ra37.
6. Cabello-Verrugio, C., Cordova, G. and Salas, J. D. (2012a). Angiotensin II: role in skeletal muscle atrophy. Curr. Protein Pept. Sci. 13, 560-569.
7. Cabello-Verrugio, C., Morales, M. G., Cabrera, D., Vio, C. P. and Brandan, E. (2012b). Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J. Cell Mol. Med. 16, 752-764.
8. Cabello-Verrugio, C., Morales, M. G., and Rivera, J. C., Cabrera, D. and Simon, F. (2015). Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med. Res. Rev. 35, 437-463.
9. Childs, T. E., and Spangenburg, E. E., Vyas, D. R. and Booth, F. W. (2003). Temporal alterations in protein signaling cascades during recovery from muscle atrophy. Am. J. Physiol. Cell Physiol. 285, C391-C398.
10. Cisternas, F., and Morales, M. G., Meneses, C., Simon, F., Brandan, E., Abrigo, J., Vazquez, Y. and Cabello-Verrugio, C. (2015). Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism. Clin. Sci. 128, 307-319.
11. Clemmons, D. R. (2009). Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol. Metab. 20, 349-356.
12. Coleman, M. E., DeMayo, F., Yin, K. C., and Lee, H. M., Geske, R., Montgomery, C. and Schwartz, R. J. (1995). Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 270, 12109-12116.
13. Criswell, D. S., and Booth, F. W., DeMayo, F., Schwartz, R. J., Gordon, S. E. and Fiorotto, M. L. (1998). Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy. Am. J. Physiol. 275, E373-E379.
14. Diffee, G. M., Kalfas, K., Al-Majid, S. and McCarthy, D. O. (2002). Altered expression of skeletal muscle myosin isoformsin cancer cachexia. Am. J. Physiol. Cell Physiol. 283, C1376-C1382.
15. Foletta, V. C., and White, L. J., Larsen, A. E., Leger, B. and Russell, A. P. (2011). The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Pflugers Arch. 461, 325-335.
16. Frost, R. A. and Lang, C. H. (2007). Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J. Appl. Physiol. 103, 378-387.
17. Gomes-Santos, I. L., Fernandes, T., Couto, G. K., Ferreira-Filho, J. C. A., Salemi, V. M. C., Fernandes, F. B., Casarini, D. E., Brum, P. C., Rossoni, L. V., de Oliveira, E. M. et al. (2014). Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats. PLoS ONE 9, e98012.
18. Hornberger, T. A., and Hunter, R. B., Kandarian, S. C. and Esser, K. A. (2001). Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats. Am. J. Physiol. Cell Physiol. 281, C179-C187.
19. Krawiec, B. J., and Frost, R. A., Vary, T. C., Jefferson, L. S. and Lang, C. H. (2005). Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 289, E969-E980.
20. Latres, E., and Amini, A. R., Amini, A. A., Griffiths, J., Martin, F. J., Wei, Y., and Lin, H. C., Yancopoulos, G. D. and Glass, D. J. (2005). Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280, 2737-2744.
21. Lecker, S. H., Solomon, V., Mitch, W. E. and Goldberg, A. L. (1999). Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr. 129, 227S-237S.
22. Meneses, C., and Morales, M. G., Abrigo, J., Simon, F., Brandan, E. and Cabello-Verrugio, C. (2015). The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice. Pflugers Arch. 467, 1975-1984.
23. Morales, M. G., Cabello-Verrugio, C., Santander, C., Cabrera, D., Goldschmeding, R. and Brandan, E. (2011). CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. J. Pathol. 225, 490-501.
24. Morales, M. G., Vazquez, Y., Acuna, M. J., and Rivera, J. C., Simon, F., Salas, J. D., Álvarez Ruf, J., Brandan, E. and Cabello-Verrugio, C. (2012). Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int. J. Biochem. Cell Biol. 44, 1993-2002.
25. Morales, M. G., Cabrera, D., Cespedes, C., Vio, C. P., Vazquez, Y., Brandan, E. and Cabello-Verrugio, C. (2013). Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res. 353, 173-187.
26. Morales, M. G., Abrigo, J., Meneses, C., Cisternas, F., Simon, F. and Cabello-Verrugio, C. (2015). Expression of the Mas receptor is upregulated in skeletal muscle wasting. Histochem. Cell Biol. 143, 131-141.
27. Munoz, M. C., Giani, J. F. and Dominici, F. P. (2010). Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul. Pept. 161, 1-7.
28. Nicastro, H., and Zanchi, N. E., da Luz, C. R. and Lancha, A. H., Jr. (2011). Functional and morphological effects of resistance exercise on disuse-induced skeletal muscle atrophy. Braz. J. Med. Biol. Res. 44, 1070-1079.
29. Olguin, H. C. and Olwin, B. B. (2004). Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev. Biol. 275, 375-388.
30. Olguin, H. C., Yang, Z., Tapscott, S. J. and Olwin, B. B. (2007). Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. J. Cell Biol. 177, 769-779.
31. Peng, X.-D., Xu, P.-Z., Chen, M.-L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., and Crawford, S. E., Coleman, K. G. et al. (2003). Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17, 1352-1365.
32. Riquelme, C., and Acuna, M. J., Torrejon, J., Rebolledo, D., Cabrera, D., Santos, R. A. and Brandan, E. (2014). ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. PLoS ONE 9, e93449.
33. Sandri, M. (2008). Signaling in muscle atrophy and hypertrophy. Physiology 23, 160-170.
34. Santos, R. A. S., Simoes e Silva, A. C., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M. et al. (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 100, 8258-8263.
35. Schakman, O., Gilson, H., de Coninck, V., Lause, P., Verniers, J., Havaux, X., Ketelslegers, J. M. and Thissen, J. P. (2005). Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146, 1789-1797.
36. Schindler, C., Bramlage, P., Kirch, W. and Ferrario, C. M. (2007). Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc. Health Risk Manag. 3, 125-137.
37. Schmittgen, T.D., Zakrajsek, B. A., Mills, A.G., Gorn, V., Singer, M.J. and Reed, M. W. (2000). Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal. Biochem. 285, 194-204.
38. Solinski, H. J., Gudermann, T. and Breit, A. (2014). Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol. Rev. 66, 570-597.
39. Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D. and Glass, D. J. (2004). The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14, 395-403.
40. Walther, T., Balschun, D., Voigt, J.-P., Fink, H., Zuschratter, W., Birchmeier, C., Ganten, D. and Bader, M. (1998). Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. 273, 11867-11873.
41. Winer, J., Jung, C. K. S., Shackel, I. and Williams, P. M. (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270, 41-49.
42. Yoshida, T., Semprun-Prieto, L., Sukhanov, S. and Delafontaine, P. (2010). IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 298, H1565-H1570.